Yonhap Infomax NewsJul 25, 2025
Hanmi Pharmaceutical Co., Ltd. reported a 4.0% rise in Q2 operating profit to 60.4 billion won, beating market expectations on strong sales of Rosuzet and Amosartan, and growth in its high-margin CDMO business, despite a 4.5% drop in revenue.
#YonhapInfomax #HanmiPharmaceutical #OperatingProfit #Rosuzet #CDMOBusiness #Q2Earnings #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=73926
Hanmi Pharmaceutical Posts Q2 Operating Profit of 60.4 Billion Won on Growth of Rosuzet and Amosartan (Comprehensive)

Hanmi Pharmaceutical Co., Ltd. reported a 4.0% rise in Q2 operating profit to 60.4 billion won, beating market expectations on strong sales of Rosuzet and Amosartan, and growth in its high-margin CDMO business, despite a 4.5% drop in revenue.

Yonhap Infomax
Yonhap Infomax NewsJul 22, 2025
Hanmi Pharmaceutical is expected to post solid Q2 results despite seasonal headwinds, with high-margin product sales offsetting weak API exports and subsidiary performance.
#YonhapInfomax #HanmiPharmaceutical #Q2Earnings #OperatingProfit #Rosuzet #Amozaltan #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=73062
Hanmi Pharmaceutical Expected to Deliver Solid Q2 Results Despite Off-Season—'High-Margin Product Sales Drive Performance'

Hanmi Pharmaceutical is expected to post solid Q2 results despite seasonal headwinds, with high-margin product sales offsetting weak API exports and subsidiary performance.

Yonhap Infomax